Drug Profile
Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical
Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; OP-01-Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical; Oral RARa agonist - Syros Pharmaceuticals; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Childrens Hospital Los Angeles; CytRx Corporation; Gyre Therapeutics; Nagoya University; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
- Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Retinoic acid receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute promyelocytic leukaemia
- Phase III Myelodysplastic syndromes
- Phase II Acute myeloid leukaemia
- Phase I/II Pancreatic cancer
- No development reported Neutropenia; Solid tumours
- Discontinued Crohn's disease; HER2 positive breast cancer; Liver cancer; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 10 Apr 2024 Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical receives Fast Track designation for Acute myeloid leukaemia [PO] (Combination therapy, First-line therapy) in USA
- 27 Mar 2024 Syros Pharmaceuticals has patents pending for Tamibarotene in the US, the Europe, Japan, Australia, Canada, China, Russia, Israel and Mexico
- 27 Mar 2024 Syros Pharmaceuticals anticipates to launch tamibarotene for Myelodysplastic syndrome (HR-MDS) in USA